NMT Medical (Boston) said its StarFlex device did not achieve its primary endpoint in the company's CLOSURE I trial for patent foramen ovale (PFO)/stroke and transient ischemic attack (TIA) trial in the U.S. The preliminary results did, however, indicate that closure with StarFlex provided a "small, but not statistically significant" benefit over current best medical therapy, NMT said. (Medical Device Daily) Read More
